Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Basic Research

Prognostic significance of YWHAZ expression in localized prostate cancer

Prostate Cancer and Prostatic Diseases volume 17, pages 310–314 (2014)Cite this article

Subjects

Abstract

Background:

Prostate cancer (PCa) patients are often over-treated because of the lack of biomarkers needed to distinguish the lethal from the indolent form of PCa. YWHAZ was recently identified as a potential therapeutic target in castration-resistant PCa (CRPC). Therefore, this study focused on determining the prognostic significance of YWHAZ in localized PCa.

Methods:

YWHAZ expression was assessed by immunohistochemistry on formalin-fixed paraffin-embedded tissue from 213 men who underwent radical prostatectomy. Kaplan–Meier analysis and Cox proportional-hazards models were used to assess the prognostic value of YWHAZ intensity.

Results:

High YWHAZ expression was strongly associated with high Gleason score at the time of diagnosis (P<0.001) and PSA relapse (P=0.001). Importantly, patients with high expression of YWHAZ had a higher risk of CRPC development (P=0.002) and reduced survival time (P=0.002).

Conclusions:

Our findings indicate that YWHAZ could serve as a promising prognostic biomarker in localized PCa to predict poor prognosis and to identify a subgroup of tumors, which might benefit from earlier adjuvant or YWHAZ-targeted therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11–30.

    Article  PubMed  Google Scholar 

  2. Turkbey B, Mena E, Aras O, Garvey B, Grant K, Choyke PL . Functional and molecular imaging: applications for diagnosis and staging of localised prostate cancer. Clin Oncol 2013; 25: 451–460.

    Article  CAS  Google Scholar 

  3. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250–1261.

    CAS  PubMed  Google Scholar 

  4. Schwartz KL . Alibhai, Shabbir MH, Tomlinson G, Naglie G, Krahn MD. Continued undertreatment of older men with localized prostate cancer. Urology 2003; 62: 860–865.

    Article  PubMed  Google Scholar 

  5. Tzivion G, Gupta VS, Kaplun L, Balan V . 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 2006; 16: 203–213.

    Article  CAS  PubMed  Google Scholar 

  6. Gardino AK, Smerdon SJ, Yaffe MB . Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. Semin Cancer Biol 2006; 16: 173–182.

    Article  CAS  PubMed  Google Scholar 

  7. Matta A, Siu KW, Ralhan R. 14-3-3 zeta as novel molecular target for cancer therapy. Expert Opin Ther Targets 2012; 16: 515–523.

    Article  CAS  PubMed  Google Scholar 

  8. Bajpai U, Sharma R, Kausar T, Dattagupta S, Chattopadhayay TK, Ralhan R . Clinical significance of 14-3-3 zeta in human esophageal cancer. Int J Biol Markers 2008; 23: 231–237.

    Article  CAS  PubMed  Google Scholar 

  9. Matta A, Bahadur S, Duggal R, Gupta SD, Ralhan R . Over-expression of 14-3-3zeta is an early event in oral cancer. BMC Cancer 2007; 7: 169.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Matta A, DeSouza LV, Shukla NK, Gupta SD, Ralhan R, Siu KW . Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry. J Proteome Res 2008; 7: 2078–2087.

    Article  CAS  PubMed  Google Scholar 

  11. Fan T, Li R, Todd NW, Qiu Q, Fang H, Wang H et al. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 2007; 67: 7901–7906.

    Article  CAS  PubMed  Google Scholar 

  12. Yang X, Cao W, Zhou J, Zhang W, Zhang X, Lin W et al. 14-3-3zeta positive expression is associated with a poor prognosis in patients with glioblastoma. Neurosurgery 2011; 68: 932–938.

    Article  PubMed  Google Scholar 

  13. Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J et al. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 2009; 69: 3425–3432.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Neal CL, Yu D . 14-3-3zeta as a prognostic marker and therapeutic target for cancer. Expert Opin Ther Targets 2010; 14: 1343–1354.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Menon R, Deng M, Ruenauver K, Queisser A, Offermann A, Boehm D et al. Somatic copy number alterations by whole exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer. J Pathol 2013; 231: 505–516.

    Article  CAS  PubMed  Google Scholar 

  16. Nowak M, Svensson MA, Carlsson J, Vogel W, Kebschull M, Wernert N et al. Prognostic significance of phospho-histone H3 in prostate carcinoma. World J Urol 2013; 32: 703–707.

    Article  PubMed  Google Scholar 

  17. Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010; 23: 1061–1067.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Braun M, Kirsten R, Rupp NJ, Moch H, Fend F, Wernert N et al. Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histol Histopathol 2013; 28: 605–610.

    PubMed  Google Scholar 

  19. Bangma CH, Roemeling S, Schroder FH . Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007; 25: 3–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Niemantsverdriet M, Wagner K, Visser M, Backendorf C . Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene 2008; 27: 1315–1319.

    Article  CAS  PubMed  Google Scholar 

  21. Murata T, Takayama K, Urano T, Fujimura T, Ashikari D, Obinata D et al. 14-3-3zeta, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival. Clin Cancer Res 2012; 18: 5617–5627.

    Article  CAS  PubMed  Google Scholar 

  22. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR . Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724–731.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Wilhelm Sander Foundation (2011.077.1), the Rudolf-Becker-Foundation and the German Research Foundation (Deutsche Forschungsgemeinschaft (DFG), Emmy-Noether-Program, PE1179/2-1) to SP. Furthermore, the project was supported by the medical student research grant of the Medical Faculty of the University of Bonn (BONFOR) to KR.

Author information

Author notes

  1. K Rüenauver, R Menon, M Nowak and S Perner: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Prostate Cancer Research, Institute of Pathology, University Hospital of Bonn, Bonn, Germany,

    K Rüenauver, R Menon, W Vogel, M Nowak & S Perner

  2. Department of Laboratory Medicine, University Hospital of Örebro, Örebro, Sweden,

    M A Svensson

  3. Department of Urology, University Hospital of Örebro, Örebro, Sweden,

    M A Svensson, J Carlsson & O Andrén

  4. Institute of Health and Medical Science, University of Örebro, Örebro, Sweden,

    M A Svensson, J Carlsson & O Andrén

  5. Member of the Transdisciplinary Prostate Cancer Partnership (ToPCaP),

    M A Svensson, J Carlsson & O Andrén

Authors
  1. K Rüenauver
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Menon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M A Svensson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Carlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O Andrén
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Nowak
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Perner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Perner.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rüenauver, K., Menon, R., Svensson, M. et al. Prognostic significance of YWHAZ expression in localized prostate cancer. Prostate Cancer Prostatic Dis 17, 310–314 (2014). https://doi.org/10.1038/pcan.2014.32

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2014.32

This article is cited by

Search

Advanced search

Quick links